Shamik J. Parikh - 18 May 2026 Form 4 Insider Report for Humacyte, Inc. (HUMA)

Reporting relationship: Chief Medical Officer
Issuer ticker: HUMA
Reported as of: 18 May 2026
Net transaction value: -$41,147
SEC form: 4
Accepted by SEC: 20 May 2026, 16:30:31 UTC
Prior SEC filing: 17 Nov 2025
Source filing: View source filing
Reporting owner signature: /s/ Shamik J. Parikh by Dale A. Sander as Attorney-in-Fact

Key filing fact

Shamik J. Parikh filed Form 4 for Humacyte, Inc. (HUMA) on 20 May 2026.

Key facts

This page summarizes Shamik J. Parikh's Form 4 filing for Humacyte, Inc. (HUMA).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 20 May 2026, 16:30.

Change

Previous filing in this sequence was filed on 17 Nov 2025.
Current net transaction value: -$41,147.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001916853 Primary reporting owner

Parikh Shamik J

Relationship: Chief Medical Officer
Address: 2525 EAST NORTH CAROLINA HIGHWAY 54, DURHAM
Signature: /s/ Shamik J. Parikh by Dale A. Sander as Attorney-in-Fact
Signature date: 20 May 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

HUMA transaction

Common Stock

Sale

Transaction value: $41,147
Shares: -45,887
Change %: -14%
Price: $0.8967
Shares after: 272,713
Date: 18 May 2026
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 1 footnote

Footnote F1

Represents the number of shares of Common Stock sold under an automated program to cover the statutory tax withholding obligations in connection with the vesting of restricted stock units previously granted to the Reporting Person. This sale was mandated by the Issuer's practice to require the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell-to-cover" transaction pursuant to a plan entered into by the Reporting Person for the purchase or sale of equity securities of the Issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c), and therefore does not represent a discretionary sale by the Reporting Person.